Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26


The efficacy of attention bias modification therapy in cocaine use disorders.

Mayer AR, Wilcox CE, Dodd AB, Klimaj SD, Dekonenko CJ, Claus ED, Bogenschutz M.

Am J Drug Alcohol Abuse. 2016 Jul;42(4):459-68. doi: 10.3109/00952990.2016.1151523. Epub 2016 May 16.


Measures of outcome for stimulant trials: ACTTION recommendations and research agenda.

Kiluk BD, Carroll KM, Duhig A, Falk DE, Kampman K, Lai S, Litten RZ, McCann DJ, Montoya ID, Preston KL, Skolnick P, Weisner C, Woody G, Chandler R, Detke MJ, Dunn K, Dworkin RH, Fertig J, Gewandter J, Moeller FG, Ramey T, Ryan M, Silverman K, Strain EC.

Drug Alcohol Depend. 2016 Jan 1;158:1-7. doi: 10.1016/j.drugalcdep.2015.11.004. Epub 2015 Nov 21. Review.


Guanfacine enhances inhibitory control and attentional shifting in early abstinent cocaine-dependent individuals.

Fox H, Sofuoglu M, Sinha R.

J Psychopharmacol. 2015 Mar;29(3):312-23. doi: 10.1177/0269881114562464. Epub 2015 Jan 7.


Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population.

McDermott KA, Griffin ML, Connery HS, Hilario EY, Fiellin DA, Fitzmaurice GM, Weiss RD.

J Clin Psychiatry. 2015 Feb;76(2):189-94. doi: 10.4088/JCP.14m09096.


Clinically relevant characteristics associated with early treatment drug use versus abstinence.

Cochran G, Stitzer M, Nunes EV, Hu MC, Campbell A.

Addict Sci Clin Pract. 2014 Apr 4;9:6. doi: 10.1186/1940-0640-9-6.


Internet-delivered treatment for substance abuse: a multisite randomized controlled trial.

Campbell AN, Nunes EV, Matthews AG, Stitzer M, Miele GM, Polsky D, Turrigiano E, Walters S, McClure EA, Kyle TL, Wahle A, Van Veldhuisen P, Goldman B, Babcock D, Stabile PQ, Winhusen T, Ghitza UE.

Am J Psychiatry. 2014 Jun;171(6):683-90. doi: 10.1176/appi.ajp.2014.13081055. Erratum in: Am J Psychiatry. 2014 Dec 1;171(12):1338.


Biomarkers for the development of new medications for cocaine dependence.

Bough KJ, Amur S, Lao G, Hemby SE, Tannu NS, Kampman KM, Schmitz JM, Martinez D, Merchant KM, Green C, Sharma J, Dougherty AH, Moeller FG.

Neuropsychopharmacology. 2014 Jan;39(1):202-19. doi: 10.1038/npp.2013.210. Epub 2013 Aug 27. Review.


Recovering from cocaine: insights from clinical and preclinical investigations.

Hanlon CA, Beveridge TJ, Porrino LJ.

Neurosci Biobehav Rev. 2013 Nov;37(9 Pt A):2037-46. doi: 10.1016/j.neubiorev.2013.04.007. Epub 2013 Apr 27. Review.


Factors in sustained recovery from cocaine dependence.

McKay JR, Van Horn D, Rennert L, Drapkin M, Ivey M, Koppenhaver J.

J Subst Abuse Treat. 2013 Aug;45(2):163-72. doi: 10.1016/j.jsat.2013.02.007. Epub 2013 Apr 2.


Initiation of abstinence in adolescents treated for marijuana use disorders.

Brown PC, Budney AJ, Thostenson JD, Stanger C.

J Subst Abuse Treat. 2013 Apr;44(4):384-90. doi: 10.1016/j.jsat.2012.08.223. Epub 2012 Oct 22.


Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial.

Mariani JJ, Pavlicova M, Bisaga A, Nunes EV, Brooks DJ, Levin FR.

Biol Psychiatry. 2012 Dec 1;72(11):950-6. doi: 10.1016/j.biopsych.2012.05.032. Epub 2012 Jul 12.


Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.

Haile CN, Mahoney JJ 3rd, Newton TF, De La Garza R 2nd.

Pharmacol Ther. 2012 May;134(2):260-77. doi: 10.1016/j.pharmthera.2012.01.010. Epub 2012 Jan 31. Review.


Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial.

Elkashef A, Kahn R, Yu E, Iturriaga E, Li SH, Anderson A, Chiang N, Ait-Daoud N, Weiss D, McSherry F, Serpi T, Rawson R, Hrymoc M, Weis D, McCann M, Pham T, Stock C, Dickinson R, Campbell J, Gorodetzky C, Haning W, Carlton B, Mawhinney J, Li MD, Johnson BA.

Addiction. 2012 Jul;107(7):1297-306. doi: 10.1111/j.1360-0443.2011.03771.x. Epub 2012 Feb 28. Erratum in: Addiction. 2012 Sep;107(9):1718. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.


Design and methodological considerations of an effectiveness trial of a computer-assisted intervention: an example from the NIDA Clinical Trials Network.

Campbell AN, Nunes EV, Miele GM, Matthews A, Polsky D, Ghitza UE, Turrigiano E, Bailey GL, VanVeldhuisen P, Chapdelaine R, Froias A, Stitzer ML, Carroll KM, Winhusen T, Clingerman S, Perez L, McClure E, Goldman B, Crowell AR.

Contemp Clin Trials. 2012 Mar;33(2):386-95. doi: 10.1016/j.cct.2011.11.001. Epub 2011 Nov 9.


Baseline matters: the importance of covariation for baseline severity in the analysis of clinical trials.

Nunes EV, Pavlicova M, Hu MC, Campbell AN, Miele G, Hien D, Klein DF.

Am J Drug Alcohol Abuse. 2011 Sep;37(5):446-52. doi: 10.3109/00952990.2011.596980.


New medications for the treatment of cocaine dependence.

Kampman KM.

Psychiatry (Edgmont). 2005 Dec;2(12):44-8.


Methylphenidate attenuates limbic brain inhibition after cocaine-cues exposure in cocaine abusers.

Volkow ND, Wang GJ, Tomasi D, Telang F, Fowler JS, Pradhan K, Jayne M, Logan J, Goldstein RZ, Alia-Klein N, Wong C.

PLoS One. 2010 Jul 9;5(7):e11509. doi: 10.1371/journal.pone.0011509.


Contingency management for cocaine use in methadone maintenance patients: when does abstinence happen?

Weinstock J, Rash CJ, Petry NM.

Psychol Addict Behav. 2010 Jun;24(2):282-91. doi: 10.1037/a0017542.


A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period.

Bisaga A, Aharonovich E, Cheng WY, Levin FR, Mariani JJ, Raby WN, Nunes EV.

Drug Alcohol Depend. 2010 Sep 1;111(1-2):97-104. doi: 10.1016/j.drugalcdep.2010.04.006. Epub 2010 May 26.

Items per page

Supplemental Content

Write to the Help Desk